Glioblastoma, a grade IV astrocytoma, has a poor survival rate in part due to ineffective treatment options available. These tumours are heterogeneous with areas of low oxygen levels, termed hypoxic regions. Many intra-cellular signalling pathways, including DNA repair, can be altered by hypoxia. Since DNA damage induction and subsequent activation of DNA repair mechanisms is the cornerstone of glioblastoma treatment, alterations to DNA repair mechanisms could have a direct influence on treatment success. Our aim was to elucidate the impact of chronic hypoxia on DNA repair gene expression in a range of glioblastoma cell lines. We adopted a NanoString transcriptomic approach to examine the expression of 180 DNA repair related genes in four classical glioblastoma cell lines (U87-MG, U251-MG, D566-MG, T98G) exposed to 5 days of normoxia (21% O 2 ), moderate (1% O 2 ) or severe (0.1% O 2 ) hypoxia. We observed altered gene expression in several DNA repair pathways including homologous recombination repair, non-homologous end-joining and mismatch repair, with hypoxia primarily resulting in downregulation of gene expression. The extend of gene expression changes was function of the hypoxic severity. Some, but not all, of these downregulations were directly under the control of HIF activity. For example, the downregulation of LIG4, a key component of non-homologous end-joining, was reversed upon inhibition of the hypoxia inducible factor (HIF). In contrast, the downregulation of the mismatch repair gene, PMS2, was not affected by HIF inhibition. This suggests that numerous molecular mechanisms lead to hypoxia-induced reprogramming of the transcriptional landscape of DNA repair. Whilst the global impact of hypoxia on DNA repair gene expression is likely to lead to genomic instability, tumorigenesis and reduced sensitivity to anti-cancer treatment, treatment re-sensitizing might require additional approaches to a simple HIF inhibition.
To explore the global impact of tumour hypoxia on the expression of DNA repair Interestingly, increasing hypoxic severity from 1% to 0.1% O 2 drastically enhanced the 121 regulation of each annotation group, especially in D566-MG cells (Fig 1) and also increased 122 the number of significantly regulated genes in this cell line ( Fig 2C) . Beyond the specific D566-123 MG cells, more genes reached statistical significance at 0.1% O 2 in all cell lines, with the 124 exception of U251-MG ( Fig 2B) . In U87-MG, 20 genes reached the strictest significance 125 threshold of p<0.001 in 0.1% O 2 compared to 10 genes in 1% O 2 (Fig 2A) . In contrast, T98G 126 displayed strong fold changes yet few genes reached statistical significance ( Fig 2D) . To 127 validate the NanoString results and determine the robustness of the data, several gene 128 candidates, regulated in more than one cell line, were measured by RT-PCR and showed good 129 consistency ( Fig S1) . The NanoString assay therefore enabled us to successfully and robustly 130 assess the extent of DNA repair gene expression alteration in GBM cell lines exposed to chronic 131 hypoxia. The mismatch repair pathway removes incorrectly inserted nucleotides added during 143 DNA replication, or removes modified bases generated by a DNA damaging agent. A sliding 144 clamp composed of MutSα (MSH2, MSH6) and MutLα (MLH1, PMS2) actively translocates 145 along the DNA in search of discontinuity (32) (33) (34) (35) . EXO1 is responsible for nucleotide excision, 146 and DNA polymerases replaces excised nucleotides (36, 37) . The expression of 13 components 147 of MMR were assessed in the NanoString assay ( Fig 3A, B ). Whilst MSH6, part of the MutSα 148 complex, was unaffected by hypoxia, MSH2 was strongly downregulated 2.3-fold in D566-MG 149 and 2.0-fold in T98G incubated in 0.1% O 2 ( Fig 3B) . PMS2, a central component of the MutLα
Discussion

240
Tumour hypoxia plays an essential role in tumour progression, metastasis and drug 241 resistance, leading to poor patient outcome particularly for GBM patients. Hypoxia has been 242 shown to impact numerous signalling pathways including the cell cycle, metabolism and 243 apoptosis, yet additionally hypoxia can have a significant impact on DNA repair mechanisms 244 We have shown here that several key DNA repair pathways were downregulated by hypoxia, 245 including MMR and NHEJ, both essential pathways for the repair of modified/mismatch bases 246 and double strand breaks respectively. Further analysis determined that PMS2 (MMR) and 247 LIG4 (NHEJ), essential components of their respective pathways, were downregulated across 248 multiple cell lines after chronic and acute hypoxic exposure, providing potential targets for re-249 sensitisation of hypoxic tumour cells to DNA damaging therapies.
251 Mismatch repair an essential repair pathway for TMZ efficacy 252
We observed hypoxia-induced downregulation of PMS2 ( Figure 3A 255 Defects in any of the critical MMR repair proteins (PMS2, MLH1, MSH2, MSH6), can lead to 256 hypermutation and microsatellite instability, due to the increased number of point mutations 257 (49) . These point mutations drive tumorigenesis and cancer progression, which will directly 258 contribute to poor patient outcome. In multicellular brain tumour spheroids, downregulation of 259 PMS2 and MLH1 promoted the initiation of tumour cell formation and growth (50) . In addition, 260 in 1996, the link between MMR and cisplatin resistance was established, when cisplatin-261 resistant human ovarian adenocarcinoma cells were found to have reduced MLH1 protein 262 (51) . In the same year, the downregulation of both MLH1 and MLH2 was found to induce 263 cisplatin and carboplatin resistance (52), although this was only a low-level resistance. We 264 see little change in the gene expression of MLH1 and MLH2, however, previously, we have 265 reported that indeed, hypoxia causes low level resistance to cisplatin in GBM cells (30) , which 266 could be due to PMS2 downregulation. More importantly for GBM, MMR is essential for TMZ-267 induced apoptosis (53) . Loss of MSH6 has been associated with increased tumour 268 progression during temozolomide treatment in GBM (54) , and alterations of MSH2 expression 269 can predict patient response to temozolomide therapy, with reduced expression correlating 270 with decreased overall patient survival (55) . Downregulation of PMS2 in hypoxia could have a 271 significant clinical impact for GBM by contributing to increased mutation rate driving 272 tumorigenesis and reduced sensitivity to temozolomide.
273
274 DNA Ligase IV is crucial for NHEJ fidelity 275 NHEJ, a highly error prone repair process, is essential for effective induction of 276 apoptosis by temozolomide treatment (56) . Among the the key components of NHEJ, we 277 observed a significant hypoxia-induced downregulation of LIG4 in multiple GBM cell lines, in 278 line with previous observations (24) . DNA Ligase IV is essential for re-joining broken DNA 279 ends, yet is also required to prevent degradation of the ends of DNA, thus promoting accurate 280 re-joining (57) . Cell lines with hypermorphic mutations in LIG4, resulting in residual DNA 281 Ligase IV function, are able to perform end-joining yet with reduced fidelity. In mice, loss of a 282 single allele of LIG4 results in the formation of soft tissue sarcomas, as a result of increased 283 genomic instability (58) . Therefore, downregulation of LIG4 may reduce the effectiveness of 284 NHEJ, thereby promoting genomic instability and further fuel tumorigenesis. However, in 285 contrast, LIG4 deficient cell lines have been shown to be more sensitive to ionizing radiation 286 (59) . Additionally, work by Kondo et al found that LIG4 deficient cells were also more 287 sensitive to temozolomide and Nimustine (ACNU), and siRNA of LIG4 enhanced cell lethality 288 of both chemotherapeutics (56, 60) . Although an increased genetic instability potentially 289 arising due to LIG4 downregulation may drive development and progression of GBM, the 290 potential positive impact of increased temozolomide sensitivity may outweigh this negative 291 implication. This highlights the double-edged sword of hypoxia, where both pro-and anti-292 cancer adaptations arise, which can be complex and difficult to untangle. Discovery of 293 targeted therapies, which can exploit the anti-cancer components of tumour hypoxia would be 294 advantageous, yet for this to occur further understanding of the molecular mechanism of 295 hypoxia-induced changes needs to be gained. 303 leads to reduced gene expression (61) . However, short-term transient changes to DNA repair 304 gene expression are more commonly studied, with mechanisms both dependent and 305 independent of HIF being described. Using an inhibitor of HIF, we showed that HIF is involved 306 in the downregulation of LIG4 but not PMS2 in hypoxic GBM cells ( Figure 5B ). HIF can 307 directly modulate the transcription of genes through binding at the hypoxic response elements 308 within promoters of DNA repair genes. For example, in the MLH1 promoter, hypoxia response 309 elements have been identified (62) suggesting direct HIF regulation, yet a mechanism of 310 MLH1 downregulation independent of HIF have also been discovered (38, 62, 63) .
311
On the other hand, other genes are altered in a HIF-independent way, such as for 312 example, via the E2F transcription factor binding in hypoxia. Indeed, in normoxia, the 313 expression of BRCA1 is mediated through the binding of the activating factor E2F1 as well as 314 the E2F4/P130 suppressor. However, under hypoxic conditions, p130 binding to E2F4 is 315 enhanced, due to alterations to p130 post-translational modifications. This results in an 316 increase in E2F4/p130 transcriptional suppressor binding at the BRAC1 promoter, reducing 317 the rate of transcription (26) . Regulation of RAD51 and FANCD2 is thought to also occur by 318 an E2F related mechanism (23, 64) . The regulation of PMS2 may be through a similar 319 mechanism. 320 321 Conclusions
322
We have shown that chronic hypoxia results in the downregulation of multiple DNA 323 repair pathways in GBM including essential components of MMR and NHEJ pathways. These 324 alterations will likely not only impact chemotherapeutic treatment efficiency but also enhance 325 the tumour genomic instability, hence further fuelling its development. The development of 326 HIF inhibitors for cancer treatment is currently a popular area of research (reviewed in (65)), 327 and will undoubtedly be of great benefit for reducing the undesirable pro-tumorigenic impact 328 of hypoxia. However, HIF is not the sole regulator of the hypoxia-induced reprogramming of Data are the mean of at least two independent experiment.
